Frederick Millard
- Hematology top 5%
-
- Renal cell carcinoma treatment 9
- Prostate Cancer Treatment and Research 9
- Oncology top 10%
- Pancreatic and Hepatic Oncology Research 4
-
- Cancer Genomics and Diagnostics 4
- Genetics top 10%
-
- Testicular diseases and treatments 6
- Bladder and Urothelial Cancer Treatments 4
-
- Immunotherapy and Immune Responses 5
-
- Radiopharmaceutical Chemistry and Applications 4
- Co-authors
- P TaniPeter BerchtoldVL Jr WoodsRobert McMillanJames M. RandallRazelle KurzrockNicholas J. VogelzangIthaar Derweesh
- Journals
- Journal of Clinical Oncology (9 papers)Clinical Genitourinary Cancer (5 papers)Cancer (2 papers)
- Partner nations
- United StatesAustriaUnited Kingdom
In The Last Decade
Frederick Millard
43 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 68
- Hematology 339
- Pulmonary and Respiratory Medicine 559
- Oncology 334
- Cancer Research 157
- Genetics 97
Countries citing papers authored by Frederick Millard
This map shows the geographic impact of Frederick Millard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederick Millard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederick Millard more than expected).
Fields of papers citing papers by Frederick Millard
This network shows the impact of papers produced by Frederick Millard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederick Millard. The network helps show where Frederick Millard may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Frederick Millard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 1 | |
| 5 | 2022 | 15 | |
| 6 | 2022 | 4 | |
| 7 | 2021 | 7 | |
| 8 | 2019 | 21 | |
| 9 | 2017 | 46 | |
| 10 | 2016 | 60 | |
| 11 | Does timing of targeted therapy for metastatic renal cell carcinoma impact treatment toxicity and surgical complications? A comparison of primary and adjuvant approaches. | 2016 | 12 |
| 12 | 2014 | 68 | |
| 13 | 2014 | 82 | |
| 14 | 2013 | 15 | |
| 15 | 2013 | 30 | |
| 16 | 2008 | 39 | |
| 17 | 2003 | 43 | |
| 18 | Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. | 2001 | 75 |
| 19 | 2001 | 86 | |
| 20 | 1990 | 55 |
About Frederick Millard
Frederick Millard is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Hematology, Nephrology and Hepatology, having authored 47 papers that have together received 1.3k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (9 papers), Prostate Cancer Treatment and Research (9 papers), Testicular diseases and treatments (6 papers), Immunotherapy and Immune Responses (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers), Pancreatic and Hepatic Oncology Research (4 papers), Cancer Genomics and Diagnostics (4 papers) and Bladder and Urothelial Cancer Treatments (4 papers). The work is most often cited by research in Hematology (339 citations), Pulmonary and Respiratory Medicine (559 citations), Oncology (334 citations), Cancer Research (157 citations) and Genetics (97 citations). Frederick Millard has collaborated with scholars based in United States, Austria and United Kingdom. Frequent co-authors include P Tani, Peter Berchtold, VL Jr Woods, Robert McMillan, James M. Randall, Razelle Kurzrock, Nicholas J. Vogelzang, Ithaar Derweesh, Yota Suzuki and Hedy L. Kindler. Their work appears in journals such as Journal of Clinical Oncology, Clinical Genitourinary Cancer, Cancer, Clinical Cancer Research and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.